Herceptin: mechanisms of action and resistance

被引：355

作者：

Nahta, R

Esteva, FJ

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA

[2] Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA

来源：

CANCER LETTERS | 2006年 / 232卷 / 02期

关键词：

breast monoclonal antibodies; trastuzumab; tyrosine kinase receptor; 27(Kip1); IGF-IR;

D O I：

10.1016/j.canlet.2005.01.041

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

HER-2 is overexpressed in 20-25% of invasive breast cancers and is associated with an aggressive tumor phenotype and reduced survival rate. The HER-2 status of a tumor is the critical determinant of response to the HER-2-targeted antibody Herceptin. Thus, accurate assessment of HER-2 expression levels is essential for identifying breast cancer patients who will benefit from HER-2-targeted therapy. Herceptin combined with chemotherapy increases response rates, time to disease progression, and Survival. However, the majority of cancers that initially respond to Herceptin begin to progress again within I year. This review describes mechanisms by which Herceptin inhibits cell growth in breast cancers that overexpress HER-2 and highlights possible mechanisms contributing to Herceptin resistance. (c) 2005 Elsevier Ireland Ltd. All rights reserved.

引用

页码：123 / 138

页数：16

共 130 条

[1] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].

Agus, DB ;

Akita, RW ;

Fox, WD ;

Lewis, GD ;

Higgins, B ;

Pisacane, PI ;

Lofgren, JA ;

Tindell, C ;

Evans, DP ;

Maiese, K ;

Scher, HI ;

Sliwkowski, MX .

CANCER CELL, 2002, 2 (02) :127-137

[2] Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer [J].

Allen, LF ;

Lenehan, PF ;

Eiseman, IA ;

Elliott, WL ;

Fry, DW .

SEMINARS IN ONCOLOGY, 2002, 29 (03) :11-21

[3]

ARPINO G, 2004, BREAST CANC RES TREA, V88, P23

[4]

Bacus SS, 2004, J CLIN ONCOL, V22, p219S

[5] Phase I and II clinical trials of trastuzumab [J].

Baselga, J .

ANNALS OF ONCOLOGY, 2001, 12 :49-55

[6]

Baselga J, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.28544

[7] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].

Baselga, J ;

Tripathy, D ;

Mendelsohn, J ;

Baughman, S ;

Benz, CC ;

Dantis, L ;

Sklarin, NT ;

Seidman, AD ;

Hudis, CA ;

Moore, J ;

Rosen, PP ;

Twaddell, T ;

Henderson, IC ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744

[8] 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology [J].

Bast, RC ;

Ravdin, P ;

Hayes, DF ;

Bates, S ;

Fritsche, H ;

Jessup, JM ;

Kemeny, N ;

Locker, GY ;

Mennel, RG ;

Somerfield, MR .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1865-1878

[9] RECOMBINANT ANTI-ERBB2 IMMUNOTOXINS CONTAINING PSEUDOMONAS EXOTOXIN [J].

BATRA, JK ;

KASPRZYK, PG ;

BIRD, RE ;

PASTAN, I ;

KING, CR .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (13) :5867-5871

[10] Vaccination against HER-2/neu oncogenic protein [J].

Bernhard, H ;

Salazar, L ;

Schiffman, K ;

Smorlesi, A ;

Schmidt, B ;

Knutson, KL ;

Disis, ML .

← 1 2 3 4 5 6 7 8 9 10 →